1 completed, 1 unknown. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Unknown 1 |
| Phase 1 | 1 | Unknown 1 |
Follow KDL Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Dose Escalation Study of VS-505 in End Stage Renal Disease Patients Undergoing Hemodialysis VS-505 - End Stage Renal Disease, Hyperphosphatemia | Phase 1 / Phase 2 | Unknown | KDL Inc. | 30 | 2015-06-01 | 2016-02-08 |
| A Study of HS219 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia HS219, Placebo - Hyperphosphatemia, Chronic Kidney Disease | Phase 2 | Completed | KDL Inc. | 68 | 2009-12-01 | 2015-09-14 |
Hyperphosphatemia (2) · Kidney Failure, Chronic (1) · Renal Insufficiency, Chronic (1)
Australia (1) · Japan (1)
Johan Rosman, MD, Ph.D (1) · Masafumi Fukagawa, MD, PhD (1) · Tadao Akizawa, MD (1)